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ABSTRACT 
 
Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) 
abnormalities in 2% of patients with de novo myelodysplastic syndromes 
(MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI 
p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from 
the Spanish Group of Hematological Cytogenetics. FISH detected –17 or 17p 
abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed 
by CC: 9% of patients with a normal karyotype, 0% in non-informative 
cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 
in 4.7% of cases with an abnormal karyotype not involving chr17. Our results 
suggest that applying FISH of 17p13 to identify the number of copies of the 
TP53 gene could be beneficial in patients with a complex karyotype. We 
recommend using FISH of 17p13 in young patients with a normal karyotype or 
non-informative cytogenetics, and always in isolated del(17p) 
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Abbreviations: 
A17, abnormal karyotype with chr17 abnormalities other than i(17q), –17, 
del(17p), or add(17p) 
AML, acute myeloid leukemia 
AOUT17, abnormal karyotype with no chr17 abnormalities 
AZA, azacitidine 
CC, conventional G-banding cytogenetics 
CEP17, chromosome centromeric probe of chr17 
chr, chromosome 
CMML, chronic myelomonocytic leukemia 
del, deletion 
FAB, French–American–British 
FISH, fluorescence in situ hybridization 
GCECGH, Grupo Cooperativo Español de Citogenética Hematológica (Spanish 
Group of Hematological Cytogenetics) 
GESMD, Grupo Español de Síndromes Mielodisplásicos (Spanish Group for 
MDS) 
IPSS, International Prognostic Scoring System 
ISCN, International System for Human Cytogenetic Nomenclature 
MDS, myelodysplastic syndromes 
N1–9, normal karyotype based on 1–9 metaphases 
N10–19, normal karyotypebased on 10‒19 metaphases 
N20, normal karyotype based on ≥20 metaphases 
NM, patients with non-informative cytogenetics or no metaphases 
RA, refractory anemia 
RAEB, refractory anemia with excess blasts 
RAEB-t, refractory anemia with excess blasts in transformation 
RARS, refractory anemia with ringed sideroblasts 
R-IPSS, revised International Prognostic Scoring System  
WHO, World Health Organization 
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1.  Introduction 
 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal 
stem cell disorders, characterized by inefficient hematopoiesis, peripheral blood 
cytopenias, and an increased risk of progression to acute myeloid leukemia 
(AML) [1–3]. Both the prognosis and the clinical course of MDS are highly 
variable, and several scoring systems have been developed to assess 
prognosis [4–7]. 
Chromosomal abnormalities in bone marrow cells are found in 40–60% of 
MDS patients [8], while, using conventional G-banding cytogenetics(CC), 
alterations of chromosome 17 (chr17) are detected in 2% of patients with de 
novo MDS [9]. The most common abnormalities detected by CC are deletion of 
[(del)]5q, monosomy 7, del(7q), gain of chromosome 8 [add(8)], del(11q), 
del(12p), isochromosome 17q(i17q), and del(20q)[10]. 
Detection of cytogenetic abnormalities is integral to the prognostic 
evaluation of patients with MDS. The International Prognostic Scoring System 
(IPSS), which categorizes cytogenetic abnormalities as low risk, intermediate 
risk, or high risk, has become the gold standard for risk assessment in de novo 
MDS [4]. Chromosome (chr) 17 abnormalities are included in the intermediate-
risk group if they are not present in a complex karyotype. The revised IPSS(R-
IPSS) classification for cytogenetic abnormalities [11] involves five groups 
proposed by Schanz et al [12], and includes i(17q) as a single anomaly in the 
intermediate cytogenetic risk group. 
Recently, our group published a cooperative study that compared the 
prognostic impact of chr17 abnormalities (n=88) with that of other karyotypic 
abnormalities (n=1070) in patients with primary MDS [9]. In agreement with the 
R-IPSS classification, this study confirmed the intermediate prognostic impact 
ofi(17q) [11,12].It also demonstrated that different types of chr17 abnormalities 
confer different prognoses: patients with monosomy 17 (–17) as part of a 
complex karyotype were found to havethe poorest prognosis. Interestingly, it 
also demonstrated that chr17 abnormalities are more commonly associated with 
complex karyotypes than are non-chr17 abnormalities. Consequently, patients 
with chr17 abnormalities are often associated with higher-risk MDS, and 
therefore could potentially benefit from active therapies – for example, 
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hypomethylating agents, which have demonstrated efficacy in this setting in 
patients ineligible for allogeneic stem cell transplantation. Azacitidine (AZA), in 
particular, has demonstrated a survival benefit compared with conventional care 
regimens [13–15]. Thus, detection of any chr17 abnormalitiesat diagnosis is 
important, as it enables more accurate prediction of the patient’s prognosis and 
the selection of appropriate treatment options. 
Although CC is the gold standard technique for clinical karyotyping, it is 
associated with some limitations: cells must be divided from the neoplastic 
clone,and the sensitivity of the technique is relatively low. Fluorescence in situ 
hybridization (FISH) is a commonlyused technique that identifies specific 
abnormalities, does not require cell division, and can be easily 
quantified.Previous studies demonstrated the value of FISH in detectingchr5 
and 7 abnormalities in patients with MDS[16,17].The main advantage of FISH 
versus CC is the higher sensitivity, with respect to the number of cells analyzed 
(CC analyzes only 20 metaphases). However, FISH only provides information 
relating to the specific region to which the probe hybridizes; it yields no 
information about other chromosomes. 
The objective of the present study was to apply FISH of 17p to a large 
cohort of patients withde novo MDS,in whom CC had failed to detect del(17p). 
 
2.  Materials and methods 
 
2.1.  Patients  
 
Patients from hospitals belonging to the Grupo Cooperativo Español de 
Citogenética Hematológica (GCECGH; Spanish Group of Hematological 
Cytogenetics) were divided into two groups according to their cytogenetic profile 
(Group A or B depending onwhetherornot they showedlossofthe short armof 
chr17).  
Group A (n = 501) included patients in whom CC had failed to detect the 
following specific chr17 abnormalities: i(17q), –17, del(17p), or add(17p). Group 
B (n = 30) included patients with i(17q), –17, del(17p) or add(17p) detected by 
CC (alterations that involve the loss of 17p). Group A was subsequently divided 
into six subgroups: normal karyotype based on ≥20 metaphases (N20); normal 
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karyotype based on 10‒19 metaphases (N10–19);normal karyotype based on 
1–9 metaphases (N1–9); abnormal karyotype with no chr17 abnormalities 
(AOUT17); abnormal karyotype with chr17 abnormalities that not involve loss of 
ofthe short armof chr17, therefore other than i(17q), –17, del(17p), or add(17p) 
(A17); and patients with non-informative cytogenetics or no metaphases (NM). 
Our group defines cytogenetic study non informative, in those cases with less 
than 10 normal metaphases. 
 
Patients were classified according to French–American–British (FAB) 
(n=527) and/or World Health Organization (WHO) 2008 (n=423) criteria. The 
study was approved by the ethics committee of Hospital Universitari Germans 
Trias i Pujol, Badalona. All patients provided written informed consent.  
 
 
2.2.  CC and FISH analysis of TP53 
 
Prior to treatment, CC and FISH were performed on bone marrow samples 
at individual laboratories with short-term, non-stimulated cultures, following 
standard procedures. Karyotypes were defined according to the International 
System for Human Cytogenetic Nomenclature(ISCN) 2009 [18].  
FISH analyses were carried out on fixed cells. The probe set consisted of 
LSI p53/17p13.1 (Ref: 32-190008, Vysis®) with a chromosome centromeric 
probe of chr17 (CEP17; a control probe; Ref: 32-112017, Vysis®) to detect –17 
or del(17p). The number of interphase nuclei analyzed ranged from 100 to 400. 
Interphase FISH cut-off percentages varied between centers. The median cut-
off values for –17and del(17p) were 10% and 5%, respectively.  
 
3.  Theory 
 
In patients with MDS, chromosomal abnormalities have been found in up 
to 40–60% of cases [8]. By CC, alterations of chr17 are detected in 2% of 
patients with de novo MDS [9]. CC has become the gold standard for 
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karyotyping, but has limitations. FISH, for which cell division is not required, is a 
highly sensitive technique that enables examination of a large number of cells. 
Patients with de novo MDS and chr17 abnormalities typically have a poor 
prognosis and poor outcomes [9]. Thus, it is important to detect chr17 
abnormalities at the time of diagnosis of MDS patients, in order to ensure that 
the most appropriate treatment options are selected. 
We hypothesized that FISH of TP53 could potentially identify del(17p) in 
some MDS patients in whom CC had failed to detect this abnormality. 
To date, few studies have been published that describe the benefits of 
applying 17p FISH at the time of diagnosis of patients with de novo MDS. Those 
studies that have been published did not exclusively analyze del(17p) in 
patients with MDS.To our knowledge, the present study included the largest 
cohort of patients with de novo MDS in whom FISH has been applied to detect 
del(17p). 
 
4.  Results 
 
In total, 531 patients with de novo MDS from 18 hospitals belonging to the 
GCECGH were included in the study. Tables 1A and 1B show the diagnosis of 
these patients according to FAB and/or WHO 2008 criteria. Using CC, 501 
patients were found to have no i(17q), –17, del(17p), or add(17p) abnormalities 
(Group A), while 30 patients had abnormalities of these types (Group B). 
Table 2 shows the results of FISH analysis of 17p13.1(TP53) in the six Group A 
subgroups. In 13 patients (2.6%), FISH detected –17 or 17p abnormalities that 
were not detected by CC. In patients with a normal karyotype by CC, del(17p) 
was detected in 0.9% of cases. FISH did not detect del(17p) in any of the 58 
patients within conclusive CC analyses, but did detect del(17p) in 50% of 
patients classified by CC as having an abnormal karyotype involving a chr17 
abnormality other than i(17q), –17, del17p, or add(17p) (subgroup A17). These 
patients defined as A17 have an abnormal karyotype with chr17 aberration but 
notinvolve loss of the short arm of chr17. We could expect that all the patients 
did no present TP53 deletion by FISH but our results show a TP53 deletion in a 
50% of the cases. This could be explained because most of these patients 
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presented a complex karyotype and the karyotype could be by an error in 
interpretation. 
In patients classified by CC as having an abnormal karyotype not involving 
chr17 (subgroup AOUT17), FISH detected del(17p) in 4.7% of cases. 
Table 3 shows the characteristics of those patients in our study with 
del(17p) that was detected by FISH alone. 
FISH revealed deletion of TP53 in two patients with normal 
karyotype.Taking into account that FISH revealed just 25% and 27% of cells 
with deletion of TP53, we could suspect that the clone with deletion of 17p was 
not detected by CC due to low grow of tumoral cells than by a cryptic deletion. 
In seven cases with complex karyotype without a deletion of 17p by CC, FISH 
revealed TP53 deletion. These discrepancies could be explained by an error in 
the interpretation of the karyotype due to the poor morphology of the 
chromosomes and by the difficulty to define complex karyotypes. Furthermore, 
in two case with 5q- as a single anomaly detected by CC, FISH revealed 
deletion of TP53 in 33% and 79% of cells. In those cases will could argue that 
both patients presented a cryptic deletion of 17p.  
In Group B, the loss of 17p13.1 was confirmed by FISH in 25 patients 
(83.3%). However, FISH failed to confirm del(17p) in five patients 
(16.7%)(Supplementary Appendix Table A1).  
 
5.  Discussion 
 
To date, few studies have been published that demonstrate the benefits of 
applying FISH of TP53 during the diagnosis of patients with de novo MDS. To 
our knowledge, our study cohort is the largest de novo MDS population that has 
been analyzed by FISH of 17p or TP53. Table 4 summarizes the main 
previously published studies in which FISH wasused to detect del(17p)in 
patients with MDS. It should be noted that none of these studies analyzed 
del(17p) exclusively. 
Overall, 2.6% of patients in our study were found by FISH to have chr17 
abnormalities that were not detected by CC. In the majority of these cases, CC 
had indicated abnormal karyotypes. Of the 220 patients with a normal karyotype 
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by CC (analysis of 20 metaphases), FISH of TP53 detected del(17p) in only two 
patients (0.9%). Furthermore, in cases where CC was inconclusive or no 
metaphases were obtained, FISH of 17p detected no TP53 deletions. Our group 
is coordinating an international study among MDS patients with normal 
karyotype studied by SNP arrays (unpublished data, IWG-PM, MDS 
Foundation). In those cases with normal cytogenetics and deletion of TP53 by 
FISH, the application of SNP arrays demonstrated a normal karyotype that 
could be explained by the low number of cells carrying deletion of TP53 (25 and 
27% of cells by FISH). The findings could suggest that the not detection of 
del17p by cytogenetics could be due by the number of cells analyzed.  
Thus, our findings suggest that FISH of TP53 may complement CC in the 
detection of chr17 abnormalities in patients with MDS, particularly in those 
patients with other karyotype abnormalities. This may be valuable in helping to 
identify patients with a poor prognosis, who could benefit from active treatment 
options, including hypomethylating agents. 
Our findings suggest that FISH of 17p is likely to be of little benefit in 
diagnosing patients with de novo MDS who are classified by CC as having a 
normal karyotype (or with no metaphases). Therefore, we would only 
recommend the use of FISH of 17p in the diagnosis of young patients, in whom 
detection of del(17p) could lead to more appropriate treatment decisions.  
A number of recent studies have demonstrated the value of FISH analysis 
of specific abnormalities that are of particular prognostic/diagnostic importance, 
such as del(5q) and chr7 abnormalities. In a study of 716 MDS patients, Mallo 
et al. reported that FISH detected del(5q) in 6% of patients who did not appear 
to have a del(5q) abnormality when analyzed by CC [16]. Similarly, Adema et al. 
reported that, when FISH of 7q31 was performed in 773 MDS patients in whom 
CC failed to detect any chr7 abnormalities, just over 5% of the patients did 
indeed have chr7 abnormalities [17]. In both of the above studies, the authors 
recommended that FISH analysis should be mandatory in specific 
circumstances for patients in whom CC has detected no abnormalities, or for 
whom insufficient metaphases are available. Our own previous data suggest 
that FISH is also valuable in some cases to verify the presence of specific 
karyotypic abnormalities detected by CC. In a study carried out on behalf of the 
Grupo Español de Síndromes Mielodisplásicos (GESMD; Spanish Group for 
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MDS), we identified 10 patients with del(17p) according to CC, who appeared to 
have a better prognosis than expected. Subsequent FISH failed to verify 
del(17p) in any of these 10 patients [9]. 
Other studies have demonstrated the potential benefit of using a panel of 
FISH probes to screen MDS/AML patients classified by CC as having normal 
karyotypes. In one such study, Rigolin et al. analyzed 101 patients with MDS 
and a normal karyotype by CC, using FISH to detect –5/del(5q), –7/del(7q), 
add(8), and del(17p)) [19]. FISH identified abnormalities in 18 patients, including 
del(17p) in one patient (1.0%). Similarly, Cuneo et al. used a panel of eight 
FISH probes to screen 27 patients with AML secondary to MDS. Cryptic 
abnormalities were detected in eight patients, including del(17p13)(TP53) in one 
patient [20]. These observations, as well as the findings of the present study, 
demonstrate the value of FISH during the diagnosis of MDS, enabling the 
detection of abnormalities that are associated with an increased rate of 
progression to AML and a worse prognosis. 
Few published studies have assessed the use of FISH specifically to 
detect chr17 aberrations during the diagnosis of patients with de novo MDS 
(Table 4). However, several small studies have highlighted the importance of 
chr17 abnormalities in the pathogenesis of the disease. In a study of patients 
with MDS (n=11) or AML (n=6) and chr17 abnormalities [15 with unbalanced 
translocations, one with –17, and one with i(17q)], FISH identified TP53 deletion 
in 14 of the 16 patients (88%) to whom the technique was applied [21]. All but 
one of these patients had p53 mutations and/or overexpression. Similarly, in a 
study of 43 patients with del(5q) MDS (n=26)/AML (n=17), FISH confirmed 
chr17 abnormalities in 10 patients (23%), all of whom had complex karyotypes 
[22]. Moreover, TP53 mutations were detected in 17% and 53% of patients with 
isolated del(5q) or complex karyotype, respectively, and were found to be 
associated with shorter survival. These findings suggest that TP53 plays a 
pathogenic role in a proportion of patients with MDS, and that FISH analysis 
would be valuable to identify such individuals. 
In addition to being of value in identifying chr17 abnormalities in elderly 
patients with MDS, FISH may be an important tool in the assessment of cases 
of pediatric MDS. Although pediatric MDS is relatively rare, accounting for less 
than 10% of childhood hematologic diseases [23], where it does occur it is often 
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associated with chromosomal abnormalities. Using CC, chromosomal 
abnormalities are detected in more than 50% of de novo pediatric MDS cases, 
while the detection rate is higher in secondary pediatric MDS. In a study of 
pediatric MDS carried out by Silveira et al., FISH detected del(17p) in 18 of the 
19 patients (95%) [24]. By contrast, CC detected chr17 abnormalities in only six 
patients. These findings suggest that routine application of chr17 FISH should 
be considered in cases of de novo pediatric MDS. 
While we did not evaluate the prognostic impact of TP53 mutations in 
patients with MDS, we believe that it may be important to address this aspect in 
future studies. Using CC, Bejar et al. analyzed 439 patients with MDS, and 
found TP53 mutations and chr17 abnormalities in 7.5% and 24.2% of patients, 
respectively [25]. Furthermore, TP53 mutations were associated with the 
occurrence of del(17p) (p<0.001). The authors also observed that TP53 
mutations were associated with markers of poor prognosis, such as complex 
karyotypes, thrombocytopenia, and a high proportion of bone marrow blasts, 
and were found mainly in patients with intermediate-2-/high-risk IPSS 
cytogenetics (79%). After adjusting for IPSS risk group, TP53 mutations were 
associated with shorter survival, and can therefore be considered an 
independent predictor of survival. 
In the present study, –17 or 17p abnormalities were detected only by 
FISH, and not by CC, in 13 patients (2.6%). In patients with CC-detected chr17 
abnormalities that did not involve loss of 17p (subgroup A17), FISH detected 
del(17p) in 50% of cases. In these patients, FISH enabled the patients’ 
prognosis to be better defined, by determining the type of chr17 aberration 
present [9]. 
FISH detected del(17p) in 4.7% of patients who, according to CC, had an 
abnormal karyotypewithout chr17 abnormalities. By CC, these patients 
presented an abnormal karyotype without evidence of loss of TP53 (no 
deletions in the short arm of chr17);by FISH, however, loss of TP53 was 
detected. In patients in whom CC detected an abnormal karyotype and –17, 
FISH failed to confirm –17 or loss of TP53. In view of its association with a poor 
prognosis in patients with a complex karyotype [9], detection of –17 is of 
particular importance. Thus, FISH of 17p could be of great benefit in these 
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patients, enabling detection of new cases of –17 not detected by CC, and 
confirming –17 cases indicated by CC.  
 
 
6.  Conclusions 
 
The prognostic impact of chr17 abnormalities in patients with primary MDS 
is well established. Thus, the identification of the TP53 deletion does impact on 
outcome because adding FISH for the detection of TP53 deletion to CC enables 
more accurate prediction of the patient’s prognosis and the selection of 
appropriate treatment options. 
The findings of our study demonstrate that FISH provides important 
prognostic information in de novo MDS. On the basis of the results obtained, we 
recommend that FISH of 17p13 should be performed: in all patients with de 
novo MDS and a complex karyotype (with or without involvement of chr17), in 
order to identify the number of copies of TP53; and in young patients with a 
normal karyotype or non-informative cytogenetics, to better predict their 
prognosis and make more appropriate treatment decisions. Furthermore, we 
recommend that isolated del(17p) detected by CC should always be verified by 
FISH. 
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Table I 
Diagnosis of study population. 
 
A. Diagnosis of study population by FAB criteria. 
 
RA 122 
RARS 155 
CMML 0 
RAEB 124 
RAEB-t 1 
MDS-U 125 
 
 
B. Diagnosis of study population by WHO 2008 criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FAB, French–American–British; RA, refractory anemia; RARS, refractory 
anemia with ringed sideroblasts; CMML, chronic myelomonocytic leukemia; 
RAEB, refractory anemia with excess blasts; RAEB-t,refractory anemia with 
excess blasts in transformation; MDS-U, MDS unclassifiable; WHO, World 
Health Organization; RCUD, refractory cytopenia with unilineage dysplasia; 
RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory 
cytopenia with multilineage dysplasia with ringed sideroblasts; RAEB-1, 
refractory anemia with excess blasts type 1; RAEB-2, refractory anemia with 
excess blasts type 2; MDS/MPD CMML, myelodysplastic/myeloproliferative 
disease type chronic myelomonocytic leukemia; MDS/MPD no CMML, 
RA 17 
RARS 64 
RCUD 7 
RCMD 126 
RCMD-RS 17 
RAEB-1 68 
RAEB-2 43 
MDS/MPD CMML 3 
MDS/ MPD no CMML 2 
5q- Syndrome  33 
MDS-U 43 
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myelodysplastic/myeloproliferative disease no chronic myelomonocytic 
leukemia. 
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Table II 
Results of FISH analysis of 17p13.1 (TP53) in Group A. 
 
Results of CC analysis Patients 
(N = 531) 
Results of FISH analysis of 
17p , n (%) 
N20 220 2 (0.9) 
N (10–19) 27 0  
N (1–9) 20 0 
NM 58 0 
A17 6 3 (50.0) 
AOUT 17 170 8 (4.7) 
Group A (total) 501 13 (2.6%) 
 
FISH, fluorescence in situ hybridization; Group A, patients without i(17q), –17, 
del17p or add(17p) detected by CC; CC, conventional G-banding cytogenetics; 
N20, 20 normal metaphases; N (10–19), 10–19 normal metaphases; N (1–9), 
1–9 normal metaphases; NM, patients with non-informative cytogenetics or no 
metaphases; A17, abnormal karyotype with chr17 aberration but not i(17q), –17, 
del(17p) or add(17p); AOUT17, abnormal karyotype without chr17 affected; del, 
deletion. 
 
Page 20 of 41
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
Table III. Characteristics of patients with del(17p) detected by FISH alone. 
 
Subgroup FAB WHO Karyotype by CC % aberrant 
nuclei 
(FISH) 
AOUT17 RA 5q-
syndrome  
46,XY,del(5)(q31)[2]/46,XY [27]  79.2 
AOUT17 MDS-U RCMD 47,XY,der(3)t(3;?)(q11;?),del(5)(q12q
ter),+mar;  
91.7 
N20 MDS-U RCMD 46,XY[20] 25.0 
AOUT17 RAEB RAEB-II 43,XX,add(1)(q34),del(4)(q22),-10,-
13,-15[5]/idem -11,+mar[5]/46,XX[10] 
30.0 
AOUT17 RA 5q-
Syndrome 
46,XX,del(5)(q13q33)[11]/46,XX[9] 33.0 
N20 RA RCMD 46,XY[20] 27.0 
AOUT17 MDS-U MDS-U 46,XY,add(6)(p22)[8]/46,XY[12] 
nucish(TP53x1)[12/100] 
12.0 
AOUT17 MDS-U MDS-U 46,XX,der(5)t(5;14;13)(q14;q24;q21),
t(12;13)(q23;q21)[8]/46,XX[10] 
nucish (TP53x1)[12/100] 
12.0 
A17 RARS RCMD 46,XY,del(5)(q31q34),der(16;17)(q23
;q21)[8]/45,XY,der(2)t(2;5)(p?;q12), 
der(16)t(16;17)(q23;q21),-20[8] 
nucish(TP53x1)[70/100] 
70.0 
A17 RAEB RAEB-I 43,X,-Y,del(4)(q?),-5,                          
-7,t(12;?)(q22;?),t(17;?)(p11;?)[20]. 
nucish(TP53x1)[30/100] 
30.0 
AOUT17 MDS-U RAEB-II 45,X,-
X,t(X;1;20)(q21;p22;?),del(5)(q13q33
),add(7)(p11),r(20)[15] 
nucish(TP53x1)[25/100] 
25.0 
AOUT17 RAEB RCMD 45,XY,-7[7]/46,XY[12] - 
A17 RA MDS-U 45,XY,-16,t(17;20)(q11;q11)[15]/ 
47,XY,sl,+del(8)(p11),+13 [3]/ 
47,XY,sdl1,-18,+19 [2] 
59.5 
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Table IV 
Previous studies in MDS that used FISH of 17p or TP53.  
 
Authors N Characteristics Region analyzed/probe Results of FISH of 17p, n 
(%) 
Soenen 
V et al. 
(1998) 
17 MDS/AML 
15 patients with 
translocations of chr17, 1 
monosomy, 1 i(17q) 
3 YACs + D17Z1 (Vysis) 
+ D5Z2 (Omcor) 
p53 deletion observed in 
14 of 16 patients 
assessed  
Rigolin 
GM et al.  
(2001) 
101 MDS with normal 
karyotype 
Probes Vysis Downers 
Grove, IL, USA for 5q31 
band, 7q31 band, a 
chromosome- 8-
centromeric probe and 
17p13 band.  
One patient found to 
have del(17)(p13).  
Cuneo A 
et al. 
(2002) 
82 
 
Normal karyotype: 
Group A: 55 AML de novo 
Group B: 27 (21 elderly 
AML + 6 AML after MDS) 
 
17p13/p53 PSC-P1 
probe 144G9 isolated by 
J Landegent 
(Department of 
Hematology, AZ Leiden, 
The Netherlands) 
Group A: No deletions 
found. Group B: 1 case 
with del17p/13/TP53 
Silveira 
CG et al.  
(2009) 
19  Pediatric MDS patients PPARgamma and TP53 
genes. RP11-
275J11(3p25.1) and 
RP11-89D11 (17p13.1) 
Deletion of TP53 found in 
18 of 19 patients 
Sebaa A 
et al. 
(2012) 
43 26 MDS and  
17 AML with del(5q) 
EGR1 (Abbott 
Molecular, des Plaines, 
IL) 
Patients with isolated 
del(5q) or one additional 
abnormality (N = 20): no 
17p deletions found. 
Patients with complex 
karyotype (n = 23): 17p 
deletion indicated by CC 
in 15 cases, and 
confirmed by FISH in 10 
 
MDS, myelodysplastic syndromes; FISH, fluorescence in situ hybridization; 
AML, acute myeloid leukemia; chr, chromosome; del, deletion; CC, 
conventional G-banding cytogenetics. 
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Supplementary Appendix 
Table A1 
Results of CC and FISH analyses in Group B with loss of 17p by CC. 
 
FAB WHO Karyotype by CC % CG Result of 
FISH 
analysis 
% aberrant 
nuclei by 
FISH 
RAEB RAEB-2 45,XY,-7,der(5)t(5;?)(q31;?),t(9;17) 
(p13;p11)[2]/46,XY,t(9;17)(p13;p11)[1]/46,XY[1] 
75.0 + 80.0 
MDS-U RAEB-1 46,XY,i(17)(q10)[7] 100.0 + Deletion 
MDS-U RCMD 45,XY,del(7)(q22),-14,-17,+mar[8]/46,XY[3] 72.7 + Monosomy 
MDS-U RAEB-2 45,XX,-4,del(5)(q13q33),-7, 
i(17)(q10)[5]/46,XX[6] 
45.5 + Deletion 
RAEB RAEB-2 43,XX,-5,der(6)t(5;6)(q31;q25),-
12,der(13)t(12;13)(q11;p22),der(13)t(13;17)(p12;q
11),-17,-18,del(20)(q11),-21.-22,-
22,+4mar[17]/46,XX[3] 
85.0 + Monosomy  
and not 
deletion 
56.0% 
RAEB RCMD 47,XX,del(5)(q14q34),del(7)(q22),add(17p13),del(
18)(p11p13),+mar[15]/46,XX[3]. 
nucish(TP53x1)[35/100] 
83.3 + 35.0 
RAEB RAEB-1 46,XY,i(17)(q10)[4]/46,XY[12].nucish(TP53x1)[30/
100] 
25.0 + 20.0 
RAEB RAEB-1 45,XY,del(5)(q13q33),der(9)t(9;12)(p22;q13),-
12,i(17)(q10)[9]/44,XY,sl,add(8)(p22),-18[2]/ 
46,XY[2] 
84.6 + Deletion  
72.0% 
RAEB RAEB-2 46,XY,del(5)(q13q33),i(17)(q10)[2]/45,sl,-
9[13]/44,sld1,-7,dic(7;20),-20[2]/near-
tetra,sld2[3]/46,XY[2] 
90.9 + Deletion  
60.0% 
RAEB - 50,XX,+1,del(5)(q13q33),+6,+8,der(17)t(17;20)(p1
3;p11),+18[25] 
78.1 + Deletion  
44.0% 
 
RAEB 
- 46,XY,i(17)(q10)[26]/ 
46,XY[4] 
86.7 + Deletion  
62.5% 
 
RAEB 
- 46,XY,del(12)(p12),i(17)(q10)[30] 100.0 + Deletion  
84.5% 
- - 52,XX,+der(1),del(5)(q13q33),+8,del(9)(p23),+11,
+13,+14,del(17)(p11),+20[11]/ 
46,XX[24] 
31.4 + 46.0% 
MDS-U - 46,XY,i(17)(q10)[26]/ 
46,XY[4] 
86.7 + 84.0% 
RAEB - 45,X,-Y[21]/ 
43,XY,-5,-7,-8,add(15)(p13),16,-
17,add(17)(p13),+mar[21]/ 
46,XY[8] 
84.0 + Monosomy  
73.5% 
RAEB - 44,XY,-5,-7,i(10)(q10),-13,der(16)(q),i(17)(q10),-
18,+2mar[22]/ 
46,XY[15] 
59.5 + Deletion  
13,5% 
MDS-U - 46,XX,del(17)(p13)[10]/ 
46,XX[20] 
33.3 -  
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RA - 46,XX,i(17)(q10)[2]/ 
46,XXX,-9,i(17)(q10)[2]/ 
47,XX,+2,i(17)(q10)[2]/ 
46,XX[34] 
15.0 + Deletion  
89.5% 
RA - 46,XX,i(17)(q10)[30] 100.0 + Deletion 
41.5 
RA 
 
- 46,XY,i(17)(q10) [1]/ 
46,XY [29] 
3.5 -  
MDS-U - 45,XX,-4,-5,-12,-17,+3mar [4]/ 
46,XX [26] 
13.3 + Deletion  
46.0% 
RA - 46,XX,-3,del(5)(q13q33),-
6,del(7)(q?),add(11)(p15),-13,-
17,add(21)(p13),+4mar [9]/ 
46,XX [41] 
18.0 + Deletion  
47.0% 
 
RAEB 
- 43,XY,add(1q),-4,-5,-6,-7,i(8)(q10),add(12)(p13),-
16,-17,+3mar [35]/ 
46,XY [15] 
70.0 + Deletion 
47.5% 
 
RAEB 
- 44,XY,-5,-7,del(9)(q?),add(17)(p13),del(20)(q12) 
[17]46,XY [3] 
85.0 + Deletion  
71.5% 
 
RAEB 
- 45,XY,del(5)(q13q32),add(12)(p13),-
15,der(17)(t(15;17)(q10;p10)  [50] 
100.0 + Deletion  
82.5% 
MDS-U - 43,XY,der(5),-7,add(11)(p15),add(12)(p13),-13,-
16,-17,-17,+2mar/ [16]46,XY [4] 
80.0 - Other 
alterations 
RAEB - 42,XY,t(1;7)(q32;q32),-9,inv(9)(p13q13),-10,-12,-
15,-17,+3mar [4]/46,XY [16] 
20.0 + Deletion 
MDS-U - 44,XX,del(3)(q21),del(5)(q13q32),-
6,add(11)(q23),der(12)(q?),-14,add(15)(q25),-
16,add(17)(p13),+mar (94%) 
46,XX (6%) 
94.0 - Other 
alterations 
RAEB - 44,XY,del(5)(q13q23),del(7)(q22),-17,-
18,add(19)(p13),-20,add(21)(q22),-22,+2mar [50] 
100.0 - Other 
alterations 
RAEB - 44,XX,der(3)(q?),del(5)(q13q33),-6,-7,-
13,i(17)(q10),add(18)(q23),-
19,del(20)(q12),+2mar [49]/46,XX [1] 
98.0 + Deletion  
61.0% 
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Fluorescence in situ hybridization (FISH) of TP53 for the 
detection of chromosome 17 abnormalities in myelodysplastic 
syndromes 
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ABSTRACT 
 
Conventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) 
abnormalities in 2% of patients with de novo myelodysplastic syndromes 
(MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI 
p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from 
the Spanish Group of Hematologicalfor Clinical Cytogeneticsall of them 
studied by conventional cytogenetics. FISH detected –17 or 17p 
abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed 
by CCFISH detected –17 or 17p abnormalities in 13 cases (2.6%) in whom CC 
had failed:FISH  detected -17 or 17p- abnormalities in 13 cases in whom CC 
had failed0.9% of patients with a normal karyotype, 0% in non-informative 
cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 
in 4.7% of cases with an abnormal karyotype not involving chr17. Our results 
suggest that applying FISH of 17p13 to identify the number of copies of the 
TP53 gene could be beneficial in patients with a complex karyotype.On the 
basis of our findings,W we recommend using FISH of 17p13 in young patients 
with a normal karyotype or non-informative cytogenetics, and always in cases of 
isolated del(17p). 
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Chromosome 17 
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Abbreviations: 
A17, abnormal karyotype with chr17 abnormalities other than i(17q), –17, 
del(17p), or add(17p) 
AML, acute myeloid leukemia 
AOUT17, abnormal karyotype with no chr17 abnormalities 
AZA, azacitidine 
CC, conventional G-banding cytogenetics 
CEP17, chromosome centromeric probe of chr17 
chr, chromosome 
CMML, chronic myelomonocytic leukemia 
del, deletion 
FAB, French–American–British 
FISH, fluorescence in situ hybridization 
GCECGH, Grupo Cooperativo Español de Citogenética Hematológica (Spanish 
Group of Hematological Cytogenetics) 
GESMD, Grupo Español de Síndromes Mielodisplásicos (Spanish Group for 
MDS) 
IPSS, International Prognostic Scoring System 
ISCN, International System for Human Cytogenetic Nomenclature 
MDS, myelodysplastic syndromes 
N1–9, normal karyotype based on 1–9 metaphases 
N10–19, normal karyotypebased on 10‒19 metaphases 
N20, normal karyotype based on ≥20 metaphases 
NM, patients with non-informative cytogenetics or no metaphases 
RA, refractory anemia 
RAEB, refractory anemia with excess blasts 
RAEB-t, refractory anemia with excess blasts in transformation 
RARS, refractory anemia with ringed sideroblasts 
R-IPSS, revised International Prognostic Scoring System  
WHO, World Health Organization 
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1.  Introduction 
 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal 
stem cell disorders, characterized by inefficient hematopoiesis, peripheral blood 
cytopenias, and an increased risk of progression to acute myeloid leukemia 
(AML) [1–3]. Both the prognosis and the clinical course of MDS are highly 
variable, and several scoring systems have been developed to assess 
prognosis [4–7]. 
Chromosomal abnormalities in bone marrow cells are found in 40–60% of 
MDS patients [8], while, using conventional G-banding cytogenetics(CC), 
alterations of chromosome 17 (chr17) are detected in 2% of patients with de 
novo MDS [9]. The most common abnormalities detected by CC are deletion of 
[(del)]5q, monosomy 7, del(7q), gain of chromosome 8 [add(8)], del(11q), 
del(12p), isochromosome 17q(i17q), and del(20q)[10]. 
Detection of cytogenetic abnormalities is integral to the prognostic 
evaluation of patients with MDS. The International Prognostic Scoring System 
(IPSS), which categorizes cytogenetic abnormalities as low risk, intermediate 
risk, or high risk, has become the gold standard for risk assessment in de novo 
MDS [4]. Chromosome (chr)17 abnormalitiesare included inthe intermediate-risk 
group if they are not present in a complex karyotype.The revised IPSS(R-IPSS) 
classification for cytogenetic abnormalities [11]involves five groups proposed by 
Schanz et al[12], and includes i(17q) as a single anomaly in the intermediate 
cytogenetic risk group. 
Recently, our group published a cooperative study that compared the 
prognostic impact of chr17 abnormalities (n=88) with that of other karyotypic 
abnormalities (n=1070) in patients with primary MDS [9]. In agreement with the 
R-IPSS classification, this study confirmed the intermediate prognostic impact 
ofi(17q) [11,12].It also demonstrated that different types of chr17 abnormalities 
confer different prognoses: patients with monosomy 17 (–17) as part of a 
complex karyotype were found to havethe poorest prognosis. Interestingly, it 
also demonstrated that chr17 abnormalities are more commonly associated with 
complex karyotypes than are non-chr17 abnormalities. Consequently, patients 
with chr17 abnormalities are often associated with higher-risk MDS, and 
therefore could potentially benefit from active therapies – for example, 
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hypomethylating agents, which have demonstrated efficacy in this setting in 
patients ineligible for allogeneic stem cell transplantation. Azacitidine (AZA), in 
particular, has demonstrated a survival benefit compared with conventional care 
regimens [13–15]. Thus, detection of any chr17 abnormalitiesat diagnosis is 
important, as it enables more accurate prediction of the patient’s prognosis and 
the selection of appropriate treatment options. 
Although CC is the gold standard technique for clinical karyotyping, it is 
associated with some limitations: cells must be divided from the neoplastic 
clone,and the sensitivity of the technique is relatively low. Fluorescence in situ 
hybridization (FISH) is a commonlyused technique that identifies specific 
abnormalities, does not require cell division, and can be easily 
quantified.Previous studies demonstrated the value of FISH in detectingchr5 
and 7 abnormalities in patients with MDS[16,17].The main advantage of FISH 
versus CC is the higher sensitivity, with respect to the number of cells analyzed 
(CC analyzes only 20 metaphases). However, FISH only provides information 
relating to the specific region to which the probe hybridizes; it yields no 
information about other chromosomes. 
The objective of the present study was to apply FISH of 17p to a large 
cohort of patients withde novo MDS,in whom CC had failed to detect del(17p). 
 
2.  Materials and methods 
 
2.1.  Patients  
 
Patients from hospitals belonging to the Grupo Cooperativo Español de 
Citogenética Hematológica (GCECGH; Spanish Group of Hematological 
Cytogenetics) were divided into two groups according to their cytogenetic profile 
(Group A or B depending onwhetherornot they showedlossofthe short armof 
chr17).  
Group A (n = 501) included patients in whom CC had failed to detect the 
following specific chr17 abnormalities: i(17q), –17, del(17p), or add(17p). Group 
B (n = 30) included patients with i(17q), –17, del(17p) or add(17p) detected by 
CC (alterations that involve the loss of 17p). Group A was subsequently divided 
into six subgroups: normal karyotype based on ≥20 metaphases (N20); normal 
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karyotype based on 10‒19 metaphases (N10–19);normal karyotype based on 
1–9 metaphases (N1–9); abnormal karyotype with no chr17 abnormalities 
(AOUT17); abnormal karyotype with chr17 abnormalities that not involve loss of 
ofthe short armof chr17, therefore other than i(17q), –17, del(17p), or add(17p) 
(A17); and patients with non-informative cytogenetics or no metaphases (NM). 
Our group defines cytogenetic study non informative, in those cases with less 
than 10 normal metaphases. 
 
Patients were classified according to French–American–British (FAB) 
(n=527) and/or World Health Organization (WHO) 2008 (n=423) criteria. The 
study was approved by the ethics committee of Hospital Universitari Germans 
Trias i Pujol, Badalona. All patients provided written informed consent.  
 
 
2.2.  CC and FISH analysis of TP53 
 
Prior to treatment, CC and FISH were performed on bone marrow samples 
at individual laboratories with short-term, non-stimulated cultures, following 
standard procedures. Karyotypes were defined according to the International 
System for Human Cytogenetic Nomenclature(ISCN) 2009 [18].  
FISH analyses were carried out on fixed cells. The probe set consisted of 
LSI p53/17p13.1 (Ref: 32-190008, Vysis®) with a chromosome centromeric 
probe of chr17 (CEP17; a control probe; Ref: 32-112017, Vysis
®
) to detect –17 
or del(17p). The number of interphase nuclei analyzed ranged from 100 to 400. 
Interphase FISH cut-off percentages varied between centers. The median cut-
off values for –17and del(17p) were 10% and 5%, respectively.  
 
3.  Theory 
 
In patients with MDS, chromosomal abnormalities have been found in up 
to 40–60% of cases [8]. By CC, alterations of chr17 are detected in 2% of 
patients with de novo MDS [9]. CC has become the gold standard for 
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karyotyping, but has limitations. FISH, for which cell division is not required, is a 
highly sensitive technique that enables examination of a large number of cells. 
Patients with de novo MDS and chr17 abnormalities typically have a poor 
prognosis and poor outcomes [9]. Thus, it is important to detect chr17 
abnormalities at the time of diagnosis of MDS patients, in order to ensure that 
the most appropriate treatment options are selected. 
We hypothesized that FISH of TP53 could potentially identify del(17p) in 
some MDS patients in whom CC had failed to detect this abnormality. 
To date, few studies have been published that describe the benefits of 
applying 17p FISH at the time of diagnosis of patients with de novo MDS. Those 
studies that have been published did not exclusively analyze del(17p) in 
patients with MDS.To our knowledge, the present study included the largest 
cohort of patients with de novo MDS in whom FISH has been applied to detect 
del(17p). 
 
4.  Results 
 
In total, 531 patients with de novo MDS from 18 hospitals belonging to the 
GCECGH were included in the study. Tables 1A and 1B show the diagnosis of 
these patients according to FAB and/or WHO 2008 criteria. Using CC, 501 
patients were found to have no i(17q), –17, del(17p), or add(17p) abnormalities 
(Group A), while 30 patients had abnormalities of these types (Group B). 
Table 2 shows the results of FISH analysis of 17p13.1(TP53) in the six Group A 
subgroups. In 13 patients (2.6%), FISH detected –17 or 17p abnormalities that 
were not detected by CC. In patients with a normal karyotype by CC, del(17p) 
was detected in 0.9% of cases. FISH did not detect del(17p) in any of the 58 
patients within conclusive CC analyses, but did detect del(17p) in 50% of 
patients classified by CC as having an abnormal karyotype involving a chr17 
abnormality other than i(17q), –17, del17p, or add(17p) (subgroup A17). These 
patients defined as A17 have an abnormal karyotype with chr17 aberration but 
notinvolve loss of the short arm of chr17. We could expect that all the patients 
did no present TP53 deletion by FISH but our results show a TP53 deletion in a 
50% of the cases. This could be explained because most of these patients 
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presented a complex karyotype and the karyotype could be by an error in 
interpretation. 
In patients classified by CC as having an abnormal karyotype not involving 
chr17 (subgroup AOUT17), FISH detected del(17p) in 4.7% of cases. 
Table 3 shows the characteristics of those patients in our study with 
del(17p) that was detected by FISH alone.. 
FISH revealed deletion of TP53 in two patients with normal 
karyotype.Taking into account that FISH revealed just 25% and 27% of 
cells with deletion of TP53, we could suspect that the clone with deletion 
of 17p was not detected by CC due to low grow of tumoral cells than by a 
criptic deletion. In seven cases with complex karyotype  without a deletion 
of 17p by CC, FISH revealed a TP53 deletion. These discrepancies could 
be explained by an error in the interpretation of the karyotype due to the 
poor morphology of the chromosomes and by the difficulty to define 
complex karyotypes. Furthermore, iIn two case with 5q- as a single 
anomaly detected by CC, FISH revealed deletion of TP53 in 33% and 79% 
of cells. In those cases will could argue that both patients presented a 
criptic deletion of 17p.  
In Group B, the loss of 17p13.1 was confirmed by FISH in 25 patients 
(83.3%). However, FISH failed to confirm del(17p) in five patients 
(16.7%)(Supplementary Appendix Table A1).  
 
5.  Discussion 
 
To date, few studies have been published that demonstrate the benefits of 
applying FISH of TP53 during the diagnosis of patients with de novo MDS. To 
our knowledge, our study cohort is the largest de novo MDS population that has 
been analyzed by FISH of 17p or TP53. Table 4 summarizes the main 
previously published studies in which FISH wasused to detect del(17p)in 
patients with MDS. It should be noted that none of these 
studiesanalyzeddel(17p) exclusively. 
Overall, 2.6% of patients in our study were found by FISH to have chr17 
abnormalities that were not detected by CC. In the majority of these cases, CC 
Formatted: Font: Bold
Formatted: Font: Bold, Italic
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold, Italic
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold, Italic
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Heading 2
Page 33 of 41
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
had indicated abnormal karyotypes. Of the 220 patients with a normal karyotype 
by CC (analysis of 20 metaphases), FISH of TP53 detected del(17p) in only two 
patients (0.9%). Furthermore, in cases where CC was inconclusive or no 
metaphases were obtained, FISH of 17p detected no TP53 deletions. Our group 
is coordinating an international study among MDS patients with normal 
karyotype studied by SNP arrays (unpublished data, IWG-PM, MDS 
Foundation). In those cases with normal cytogenetics and deletion of TP53 by 
FISH, the application of SNP arrays demonstrated a normal karyotype that 
could be explained by the low number of cells carrying deletion of TP53 (25 and 
27% of cells by FISH). The findings could suggest that the not detection of 
del17p by cytogenetics could be due by the number of cells analyzed.  
Thus, our findings suggest that FISH of TP53 may complement CC in the 
detection of chr17 abnormalities in patients with MDS, particularly in those 
patients with other karyotype abnormalities. This may be valuable in helping to 
identify patients with a poor prognosis, who could benefit from active treatment 
options, including hypomethylating agents. 
Our findings suggest that FISH of 17p is likely to be of little benefit in 
diagnosing patients with de novo MDS who are classified by CC as having a 
normal karyotype (or with no metaphases). Therefore, we would only 
recommend the use of FISH of 17p in the diagnosis of young patients, in whom 
detection of del(17p) could lead to more appropriate treatment decisions.  
A number of recent studies have demonstrated the value of FISH analysis 
of specific abnormalities that are of particular prognostic/diagnostic importance, 
such as del(5q) and chr7 abnormalities. In a study of 716 MDS patients, Mallo 
et al. reported that FISH detected del(5q) in 6% of patients who did not appear 
to have a del(5q) abnormality when analyzed by CC [16]. Similarly, Adema et al. 
reported that, when FISH of 7q31 was performed in 773 MDS patients in whom 
CC failed to detect any chr7 abnormalities, just over 5% of the patients did 
indeed have chr7 abnormalities [17]. In both of the above studies, the authors 
recommended that FISH analysis should be mandatory in specific 
circumstances for patients in whom CC has detected no abnormalities, or for 
whom insufficient metaphases are available. Our own previous data suggest 
that FISH is also valuable in some cases to verify the presence of specific 
karyotypic abnormalities detected by CC. In a study carried out on behalf of the 
Page 34 of 41
URL: http://mc.manuscriptcentral.com/glal
Leukemia and Lymphoma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Grupo Español de Síndromes Mielodisplásicos (GESMD; Spanish Group for 
MDS), we identified 10 patients with del(17p) according to CC, who appeared to 
have a better prognosis than expected. Subsequent FISH failed to verify 
del(17p) in any of these 10 patients [9]. 
Other studies have demonstrated the potential benefit of using a panel of 
FISH probes to screen MDS/AML patients classified by CC as having normal 
karyotypes. In one such study, Rigolin et al. analyzed 101 patients with MDS 
and a normal karyotype by CC, using FISH to detect –5/del(5q), –7/del(7q), 
add(8), and del(17p)) [19]. FISH identified abnormalities in 18 patients, including 
del(17p) in one patient (1.0%). Similarly, Cuneo et al. used a panel of eight 
FISH probes to screen 27 patients with AML secondary to MDS. Cryptic 
abnormalities were detected in eight patients, including del(17p13)(TP53) in one 
patient [20]. These observations, as well as the findings of the present study, 
demonstrate the value of FISH during the diagnosis of MDS, enabling the 
detection of abnormalities that are associated with an increased rate of 
progression to AML and a worse prognosis. 
Few published studies have assessed the use of FISH specifically to 
detect chr17 aberrations during the diagnosis of patients with de novo MDS 
(Table 4). However, several small studies have highlighted the importance of 
chr17 abnormalities in the pathogenesis of the disease. In a study of patients 
with MDS (n=11) or AML (n=6) and chr17 abnormalities [15 with unbalanced 
translocations, one with –17, and one with i(17q)], FISH identified TP53 deletion 
in 14 of the 16 patients (88%) to whom the technique was applied [21]. All but 
one of these patients had p53 mutations and/or overexpression. Similarly, in a 
study of 43 patients with del(5q) MDS (n=26)/AML (n=17), FISH confirmed 
chr17 abnormalities in 10 patients (23%), all of whom had complex karyotypes 
[22]. Moreover, TP53 mutations were detected in 17% and 53% of patients with 
isolated del(5q) or complex karyotype, respectively, and were found to be 
associated with shorter survival. These findings suggest that TP53 plays a 
pathogenic role in a proportion of patients with MDS, and that FISH analysis 
would be valuable to identify such individuals. 
In addition to being of value in identifying chr17 abnormalities in elderly 
patients with MDS, FISH may be an important tool in the assessment of cases 
of pediatric MDS. Although pediatric MDS is relatively rare, accounting for less 
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than 10% of childhood hematologic diseases [23], where it does occur it is often 
associated with chromosomal abnormalities. Using CC, chromosomal 
abnormalities are detected in more than 50% of de novo pediatric MDS cases, 
while the detection rate is higher in secondary pediatric MDS. In a study of 
pediatric MDS carried out by Silveira et al., FISH detected del(17p) in 18 of the 
19 patients (95%) [24]. By contrast, CC detected chr17 abnormalities in only six 
patients. These findings suggest that routine application of chr17 FISH should 
be considered in cases of de novo pediatric MDS. 
While we did not evaluate the prognostic impact of TP53 mutations in 
patients with MDS, we believe that it may be important to address this aspect in 
future studies. Using CC, Bejar et al. analyzed 439 patients with MDS, and 
found TP53 mutations and chr17 abnormalities in 7.5% and 24.2% of patients, 
respectively [25]. Furthermore, TP53 mutations were associated with the 
occurrence of del(17p) (p<0.001). The authors also observed that TP53 
mutations were associated with markers of poor prognosis, such as complex 
karyotypes, thrombocytopenia, and a high proportion of bone marrow blasts, 
and were found mainly in patients with intermediate-2-/high-risk IPSS 
cytogenetics (79%). After adjusting for IPSS risk group, TP53 mutations were 
associated with shorter survival, and can therefore be considered an 
independent predictor of survival. 
In the present study, –17 or 17p abnormalities were detected only by 
FISH, and not by CC, in 13 patients (2.6%). In patients with CC-detected chr17 
abnormalities that did not involve loss of 17p (subgroup A17), FISH detected 
del(17p) in 50% of cases. In these patients, FISH enabled the patients’ 
prognosis to be better defined, by determining the type of chr17 aberration 
present [9]. 
FISH detected del(17p) in 4.7% of patients who, according to CC, had an 
abnormal karyotypewithout chr17 abnormalities. By CC, these patients 
presented an abnormal karyotype without evidence of loss of TP53 (no 
deletions in the short arm of chr17);by FISH, however, loss of TP53 was 
detected. In patients in whom CC detected an abnormal karyotype and –17, 
FISH failed to confirm –17 or loss of TP53. In view of its association with a poor 
prognosis in patients with a complex karyotype [9], detection of –17 is of 
particular importance. Thus, FISH of 17p could be of great benefit in these 
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patients, enabling detection of new cases of –17 not detected by CC, and 
confirming –17 cases indicated by CC.  
 
 
6.  Conclusions 
 
The prognostic impact of chr17 abnormalities in patients with primary MDS 
is well established. Thus, the identification of the TP53 deletion does impact on 
outcome because adding FISH for the detection of TP53 deletion to CC enables 
more accurate prediction of the patient’s prognosis and the selection of 
appropriate treatment options. 
It is known the prognostic impact of chr17 abnormalities in patients with 
primary MDS. Thus, the identification of the TP53 deletion does impact on 
outcome because add FISH of TP53 to CC enables more accurate prediction of 
the patient’s prognosis and the selection of appropriate treatment options”. 
The findings of our study demonstrate the value ofthat  FISH provides 
important prognostic information in diagnosing de novo MDS. On the basis of 
the results obtained, we recommend that FISH of 17p13 should be performed: 
in all patients with de novo MDS and a complex karyotype (with or without 
involvement of chr17), in order to identify the number of copies of TP53; and in 
young patients with a normal karyotype or non-informative cytogenetics, to 
better predict their prognosis and make more appropriate treatment decisions. 
Furthermore, we recommend that isolated del(17p) detected by CC should 
always be verified by FISH. 
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